Rib Cage Pain in Psoriatic Arthritis: Evaluation and Management
Rib cage pain in a patient with psoriatic arthritis should be evaluated as potential enthesitis (costochondral junction inflammation) or axial disease involvement, and managed with NSAIDs as first-line therapy, local corticosteroid injections for accessible entheseal sites, and escalation to biologic DMARDs if inadequate response, while systemic corticosteroids should be avoided. 1
Clinical Evaluation
The rib cage pain requires specific assessment for two primary PsA manifestations:
Enthesitis Assessment
- Examine costochondral joints specifically for tenderness and swelling, as these are common entheseal sites in PsA 2
- Palpate for point tenderness at rib-sternum junctions bilaterally
- Assess for other entheseal involvement (Achilles tendon, plantar fascia, elbow) to establish pattern 2
Axial Disease Evaluation
- Determine if pain has inflammatory characteristics: worse with rest, improves with activity, associated with morning stiffness
- Assess for sacroiliac joint involvement and spinal symptoms, as PsA can produce ankylosing spondylitis-like axial disease 2, 3
- Consider imaging (MRI or ultrasound) to differentiate inflammatory from mechanical causes 4
Management Algorithm
Step 1: Initial Symptomatic Treatment
Start with NSAIDs to relieve musculoskeletal pain and stiffness 1. This is appropriate for both enthesitis and axial manifestations.
Step 2: Local Therapy (for enthesitis)
Consider local corticosteroid injections for accessible costochondral entheseal sites as adjunctive therapy 1. Note that the 2024 EULAR guidelines specifically removed systemic corticosteroids from recommendations, advising they "may be used with caution" was changed to only local injections being recommended 1.
Step 3: Systemic DMARD Therapy
If NSAIDs and local measures are insufficient:
- For peripheral arthritis component: Initiate conventional synthetic DMARD (csDMARD) rapidly, with methotrexate preferred if significant skin involvement exists 1
- For axial disease/enthesitis: DMARDs like methotrexate have limited efficacy for spinal disease and enthesitis 2. Proceed directly to biologic therapy (anti-TNF agents remain gold standard) 5
Step 4: Treat-to-Target Approach
Aim for remission or minimal/low disease activity through regular monitoring and therapy adjustment 1. The 2024 EULAR guidelines emphasize this target-driven strategy as fundamental.
Critical Considerations
Multidisciplinary Assessment
Since PsA is heterogeneous, evaluate all disease domains simultaneously 1, 6:
- Peripheral arthritis pattern
- Dactylitis presence
- Skin and nail involvement severity
- Other entheseal sites
- Comorbidities (obesity, cardiovascular disease, metabolic syndrome) 1
Common Pitfalls to Avoid
- Do not use systemic corticosteroids routinely - the 2024 EULAR update specifically de-emphasized systemic steroids, recommending only local injections 1
- Do not delay biologic therapy for axial/entheseal disease - csDMARDs are ineffective for these manifestations 2
- Do not overlook that this may be the presenting symptom - up to 40% of psoriasis patients may have undiagnosed arthritis 2
Evidence Quality Note
The 2024 EULAR recommendations 1 represent the most current guideline evidence and should frame management decisions. The pain management recommendations 7 support physical activity and exercise interventions as adjuncts, though specific evidence for rib cage pain is limited. The research evidence consistently identifies enthesitis as a key diagnostic feature requiring specialist rheumatology assessment 2, 3.
Referral Considerations
Rheumatologists should primarily manage musculoskeletal manifestations 1. If not already under rheumatology care, urgent referral is warranted for suspected inflammatory rib cage pain, as early treatment prevents structural damage and optimizes quality of life 1, 8.